Alkermes is positioned for outperformance due to its conservative cash-heavy balance sheet and high-margin business model.

Throughout the last three months, 7 analysts have evaluated Alkermes (NASDAQ:ALKS), offering a diverse set of opinions from ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Alkermes (ALKS) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.01 per share a year ago. These figures are ...

DUBLIN (AP) — DUBLIN (AP) — Alkermes PLC (ALKS) on Wednesday reported first-quarter net income of $36.8 million, after reporting a loss in the same period a year earlier. The Dublin-based ...

Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise ...

Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the ...

Alkermes plc ALKS reported adjusted earnings from continuing operations of 44 cents per share for first-quarter 2024, which ...